// App-Quantinova.ai

655 : Pivotal screening and proposed treatment algorithm for immune checkpoint inhibitor–induced cardio/myotoxicities in neoadjuvant-treated rectal cancer patients: experience from the CHINOREC trial

Researchers

Presenter

  • Johannes Laengle

Principal Investigators

  • Jutta Bergler-Klein

  • Simon Hametner

  • Ellen Gelpi

  • Irene Kuehrer

  • Branka Petricevic

  • Askin Kulu

  • Clemens Bittermann

  • Anton Stift

  • Friedrich Laengle

  • Klaus Machold

  • Stephan Blueml

  • Michael Bergmann

Medical Centers

  • State Hospital Wiener Neustadt, Vienna, Austria

  • Medical University of Vienna, Vienna, Austria

Locations

  • Austria

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Colorectal Cancer

Biomarkers

  • C-C Motif Chemokine Ligand 20

  • N-terminal pro b-type natriuretic peptide

Drug/Treatment

  • Capecitabine

  • Nivolumab

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multicenteric

  • Prospective

Phase

  • II

Study Id's

  • NCT04124601

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved